2-Chlorodeoxyadenosine in the Treatment of Hairy Cell Leukemia and Chronic Lymphocytic Leukemia
Authors:
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 11 (sup2) , 109-114
Abstract
More than 450 patients with hairy cell leukemia have been treated at the Scripps Clinic. Of 144 patients followed for a median of 14.2 months (range, 8.1–70 months), 123 (85%) obtained complete responses, 17 (12%) partial responses, 3 (2%) did not respond, and 1 patient was unevaluable. So far, 4 patients have relapsed at a median of 36 months (range, 12–48 months). Fever was the principal toxicity occurring in 43% of patients. Five patients resistant (3 patients) or intolerant (2 patients) to deoxycoformycin were also treated. Of these 5 patients, 4 obtained complete responses, including 2 patients resistant to deoxycoformycin, and 1 patient a partial response, suggesting a possible lack of cross-resistance between deoxycoformycin and 2–CdA in hairy cell leukemia. Other single-institution studies have documented similar response rates and toxicities. Ninety patients with advanced chronic lymphocytic leukemia were treated with 2–CdA administered either as a 0.1 mg/kg/day 7–day continuous intravenous infusion or as a 0.028–0.14 mg/kg/day 2–hour bolus for 5 consecutive days. Four patients (4%) obtained complete responses and 36 patients (40%) partial responses, using NCI-sponsored Working Group guidelines. Of the 50 patients who were non-responders, 27 (54%) had a ≥ 50% sustained reduction in the absolute lymphocyte count. The ratio of deoxycytidine kinase to cytoplasmic 5′-nucleotidase was predictive of 2–CdA responsiveness. Fourteen patients with fludarabine-failed chronic lymphocytic leukemia were also treated. No responses were achieved and 2 patients had progressive disease. Six patients had a ≥ 50% reduction in the absolute lymphocyte count. The efficacy and safety of 2–CdA in fludarabine-failed chronic lymphocytic leukemia patients remains to be evaluated in larger numbers of patients.Keywords
This publication has 30 references indexed in Scilit:
- High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.Journal of Clinical Oncology, 1993
- Response to 2-Chlorodeoxyadenosine in Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to FludarabineNew England Journal of Medicine, 1992
- 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1991
- Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-ChlorodeoxyadenosineNew England Journal of Medicine, 1990
- Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.Journal of Clinical Investigation, 1985
- Splenectomy in hairy cell leukemia: A retrospective multicenter analysisCancer, 1981
- Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.Proceedings of the National Academy of Sciences, 1980
- Hairy Cell LeukemiaAnnals of Internal Medicine, 1978
- Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.Proceedings of the National Academy of Sciences, 1978
- ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITYThe Lancet, 1972